Last reviewed · How we verify

NCT03822429

Cumulative Live Birth Rate (CLBR) After a Complete IVF Cycle: a Single Center Retrospective Study

Completed Last updated 30 January 2019
What this trial tests

trial testing Controlled ovarian stimulation in ART in 6,375 participants. Completed in 31 December 2015.

Timeline
1 January 2010
Primary endpoint
31 December 2015
31 December 2015

Quick facts

Lead sponsorIstituto Clinico Humanitas
StatusCompleted
Study typeOBSERVATIONAL
Enrollment6,375
Start date1 January 2010
Primary completion31 December 2015
Estimated completion31 December 2015

Drugs / interventions tested

Conditions studied

Sponsor

Istituto Clinico Humanitas

Who can join

Adults 18 to 46, female only, with ART or Fertility Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We need to identify a new parameter to evaluate the success rate of IVF techniques. CLBR has been suggested as a suitable way for reporting success of IVF program: it implies capturing the totality of live birth episodes following successive treatments. For patients CLBR is easy to understand because it summarizes the chance of a live birth over an entire treatment period. CLBR per oocyte retrieval is more meaningful as it is the best indicator of quality and success in IVF and it allows the best indicator of quality and success in IVF with different strategies for freezing embryos.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for ART

Currently open trials in the same condition.

Other Istituto Clinico Humanitas trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03822429.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing